Cargando…
The treatment of amyloidosis is being refined
The therapy of transthyretin (TTR)-related cardiac amyloidosis consists, on the one hand, of the prevention and management of complications (supportive therapy) and on the other of treatments aimed at interrupting or slowing down the production and deposition of fibrils (disease-modifying therapy)....
Autores principales: | Cantone, Anna, Sanguettoli, Federico, Dal Passo, Beatrice, Serenelli, Matteo, Rapezzi, Claudio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653129/ https://www.ncbi.nlm.nih.gov/pubmed/36380794 http://dx.doi.org/10.1093/eurheartjsupp/suac104 |
Ejemplares similares
-
Transthyretin amyloidosis in aortic stenosis: clinical and therapeutic implications
por: Fabbri, Gioele, et al.
Publicado: (2021) -
Stroke volume and myocardial contraction fraction in transthyretin amyloidosis cardiomyopathy: A systematic review
por: Matteo, Serenelli, et al.
Publicado: (2023) -
Treatment of amyloidosis: present and future
por: Mallus, Maria Teresa, et al.
Publicado: (2023) -
Cardiology of the future: xenotransplantation with porcine heart
por: Sinagra, Gianfranco, et al.
Publicado: (2022) -
The myocardial bridge: incidence, diagnosis, and prognosis of a pathology of uncertain clinical significance
por: Santucci, Andrea, et al.
Publicado: (2022)